Interim Treatment Fidelity for a Randomized Controlled Comparative Effectiveness Trial of Two Variants of Semantic Feature Analysis Treatment for Aphasia.
IF 2.3 3区 医学Q1 AUDIOLOGY & SPEECH-LANGUAGE PATHOLOGY
Miranda C Babiak, William D Hula, Alyssa Autenreith, Mary M Nader, Shannon Austermann Hula, Alexander Swiderski, Robert Cavanaugh, Kristen Nunn, Jeffrey P Johnson, Michael Walsh Dickey
{"title":"Interim Treatment Fidelity for a Randomized Controlled Comparative Effectiveness Trial of Two Variants of Semantic Feature Analysis Treatment for Aphasia.","authors":"Miranda C Babiak, William D Hula, Alyssa Autenreith, Mary M Nader, Shannon Austermann Hula, Alexander Swiderski, Robert Cavanaugh, Kristen Nunn, Jeffrey P Johnson, Michael Walsh Dickey","doi":"10.1044/2025_AJSLP-24-00331","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>This study evaluated treatment fidelity for an ongoing randomized controlled trial comparing two variants of semantic feature analysis (SFA) treatment for naming impairment in aphasia. In this trial, participants are being randomized to treatment conditions (many- or few-features) in which they are asked to generate either 11 or five features per SFA trial.</p><p><strong>Method: </strong>Treatment fidelity was addressed via study design, manualization of the treatment, provider training, and maintenance of daily treatment logs, among other approaches. Fidelity was assessed through protocol adherence checks, interrater reliability of feature counting, and analysis of treatment dosage. Protocol adherence was measured using a 20-item checklist. Interrater reliability was evaluated for feature counts on 10% of treatment sessions. Treatment dosage was analyzed to confirm differentiation between many-features and few-features groups in terms of features generated and exposed and equivalence in terms of total treatment time.</p><p><strong>Results: </strong>Overall protocol adherence was 99%. Interrater reliability for feature counting showed good-to-excellent agreement. Analysis of treatment dosage in terms of features per trial confirmed clear differentiation between groups, with the many-features group generating or being exposed to approximately 10-11 features per trial compared to four to five features for the few-features group. Analysis of other aspects of dosage also suggested good fidelity to the design.</p><p><strong>Conclusions: </strong>This ongoing trial of SFA is being implemented with high levels of treatment fidelity. The study demonstrates the importance and feasibility of comprehensive fidelity monitoring in aphasia treatment research. Detailed fidelity procedures and outcomes support interpretation, replication, and clinical implementation of study findings.</p><p><strong>Supplemental material: </strong>https://doi.org/10.23641/asha.29230937.</p>","PeriodicalId":49240,"journal":{"name":"American Journal of Speech-Language Pathology","volume":" ","pages":"1-17"},"PeriodicalIF":2.3000,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Speech-Language Pathology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1044/2025_AJSLP-24-00331","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"AUDIOLOGY & SPEECH-LANGUAGE PATHOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: This study evaluated treatment fidelity for an ongoing randomized controlled trial comparing two variants of semantic feature analysis (SFA) treatment for naming impairment in aphasia. In this trial, participants are being randomized to treatment conditions (many- or few-features) in which they are asked to generate either 11 or five features per SFA trial.
Method: Treatment fidelity was addressed via study design, manualization of the treatment, provider training, and maintenance of daily treatment logs, among other approaches. Fidelity was assessed through protocol adherence checks, interrater reliability of feature counting, and analysis of treatment dosage. Protocol adherence was measured using a 20-item checklist. Interrater reliability was evaluated for feature counts on 10% of treatment sessions. Treatment dosage was analyzed to confirm differentiation between many-features and few-features groups in terms of features generated and exposed and equivalence in terms of total treatment time.
Results: Overall protocol adherence was 99%. Interrater reliability for feature counting showed good-to-excellent agreement. Analysis of treatment dosage in terms of features per trial confirmed clear differentiation between groups, with the many-features group generating or being exposed to approximately 10-11 features per trial compared to four to five features for the few-features group. Analysis of other aspects of dosage also suggested good fidelity to the design.
Conclusions: This ongoing trial of SFA is being implemented with high levels of treatment fidelity. The study demonstrates the importance and feasibility of comprehensive fidelity monitoring in aphasia treatment research. Detailed fidelity procedures and outcomes support interpretation, replication, and clinical implementation of study findings.
期刊介绍：
Mission: AJSLP publishes peer-reviewed research and other scholarly articles on all aspects of clinical practice in speech-language pathology. The journal is an international outlet for clinical research pertaining to screening, detection, diagnosis, management, and outcomes of communication and swallowing disorders across the lifespan as well as the etiologies and characteristics of these disorders. Because of its clinical orientation, the journal disseminates research findings applicable to diverse aspects of clinical practice in speech-language pathology. AJSLP seeks to advance evidence-based practice by disseminating the results of new studies as well as providing a forum for critical reviews and meta-analyses of previously published work.
Scope: The broad field of speech-language pathology, including aphasia; apraxia of speech and childhood apraxia of speech; aural rehabilitation; augmentative and alternative communication; cognitive impairment; craniofacial disorders; dysarthria; fluency disorders; language disorders in children; speech sound disorders; swallowing, dysphagia, and feeding disorders; and voice disorders.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
